In a large clinical picture, this study

Researchers at the Medical College Dzhordzhiyi develop new and interesting techniques to help avoid transplantation and acute rejection hiperostroy attack by the immune system. Entering a special ball microparticles directly on dendritic cells, the researchers were able to intervene in antigen presentation, dendritic cells that normally do. In a large clinical picture, this study may allow us to give the immune system of recipients of temporary special access to the transplanted organ to relax during which the waiver authority can be transferred. Decomposition of microparticles to deliver the most powerful of the known forms of HLA-G, podavytel natural immune response directly in dendritic cells, which usually indicate that the immune system to attack. Microparticles data immediately after transplantation as dendritic cells enable the immune system leads to do business attacking the new organ.

Microparticles therapy most likely will need a few weeks until the dendritic cells have learned instead to ignore his doctor Horuzsko says. Its like a soothing effect lasix heart failure and once tolerance is established we do not need it anymore. His lab reported its success in this method of delivery in mice with skin grafts last month in human immunology. When the researchers compared the success of HLA-G microparticles in dendritic cells marker for those without the marker, who was more effective for as necessary and effective, he says. Those without direction likely to be absorbed garbage eaters called macrophages. Unlike the current against rejection drugs that suppress the immune system usually leaving the patient vulnerable to infections, cancer and more HLA-G offers specific tolerance. The fruit, also avoid using a rejection immune system, are good examples of specific tolerance HLA-G gives Horuzsko doctor says. We want to create in kidney transplant patients, the same access to the new kidney. For five years, HLA-G microparticles could do just that, says Dr. Horuzsko. He introduced the patented process along with his friend last HLA-G, obtained during the opening lecture 5th International Conference on HLA-G in Paris on July 6-8. Marked microparticles as potential treatment of diseases which the immune system attacks healthy tissues, such as arthritis, multiple sclerosis and inflammatory bowel disease, Dr. Horuzsko says. Conversely, the method can be used to deliver compounds block HLA-G activity, which also increased in tumors. Scientists are also working with Dr. Laura Malloy, head of the Section of Nephrology, Hypertension and Transplantation Medicine in the School of Medicine MCG, to determine if higher natural rate of HLA-G already give some patients after the transplant edge by comparing HLA-G expression in those who hold and reject their transplanted kidney. HLA-G works through inhibitory receptors, ILT2, ILT3 and ILT4 on dendritic cells, inducing signaling pathway in which some molecules inhibit activated to protect the transplanted organ or tissue. Man leukocyte antigen G, or HLA-G, is actually a member of a family of genes called major histocompatibility complex, which usually cause the immune response. As errant child, HLA-G, but does not promote tolerance, the doctor says Horuzsko. Press release: